Brian Cheng: Yes. Maybe just one more on 371. Any color on clinical activity so far with the fifth cohort dosing? And just how should we think about the potential indications for the Phase II dose expansion cohort?
Jay Short: Yes. I mean, the safety wise, and we’re very happy with that. We’re also very encouraged without getting into any specifics, but with the data and readouts that we’re seeing already. And so I would say, as we said in the script, we’re excited about that asset, and we continue to be. And I think you’ll recall that we’re testing this across 8 different indications, all known to have some responsiveness to CTLA-4. And so we’re — we’ve done a fair bit of analysis on which ones we are likely to take forward, but I think we’re going to see how the next cohort reads out and tighten that view. But I think at this point, I certainly wouldn’t be ruling out any indications. However, there would be some better, I think, that have a great opportunity, and I would prefer not to list them now because this is an evolving asset and I really like the data we’re seeing with the combination with PD-1 or 3 mg per kg and clearing the 5 mg per kg and then we already have dosed the patients at this next level.
So it’s ongoing. I should add it, Brian, one nice thing about CTLA-4 is that it also opens up the door for future combination therapies. And just like in analogous way that PD-1 has done with so many different other therapies. So one can’t help but sit back and think about those possibilities in addition to just combining with PD-1 [ph].
Operator: Our next question is from Kaveri Pohlman with BTIG.
Kaveri Pohlman: Thanks. Phase II trial; it’s a relatively small sample size. Any color on when do you think you’ll be able to complete the frequent dosing study? And will you be reporting efficacy data from these cohorts after selection of the right schedule or that won’t be allowed since some patients will be part of the pivotal trial?
Jay Short: Well, if we’re talking about loans, we do anticipate — well, we’ll have the data, enough data for the more frequent dosing to make our plan for going forward to a registrational study this half of this year. We are and have identified a medical meeting where we intend to provide an update on our data both for every other week dosing as well as the more frequent dosing. We’re going to report on that meeting after we formally get accepted. — at that meeting. But we believe that’s on track for communication this year. That’s with the axle in lung. The UPS, of course, is the registration or potentially registrational now, and we’ll not be reporting on that until later next year once we get further down the line on that.
And then the ovarian studies, we intend to report out on those, both for the Asan ROI, and we’re certainly hopeful that we’ll have sufficient data on the MORE2 asset to allow us to affect the prioritization across our portfolio, both from the standpoint of what we want to take forward what we might want to partner, et cetera. I’m not sure that we’re going to report out on efficacy data on ORI this year, but we’ll certainly have some sense of the prioritization – and of course, CTLA-4, I think also we’re going to be – we’ll be giving a routine updates on as we progress to Phase 1. But I think as we’ll also guide a little bit on where we’re going to head with the Phase II study as well. The actual readout on that is probably – most of our plan, as we’ve reported earlier in the years to align with medical meetings for our readouts.
But we’re trying to bring in as many of those as we can into this year.
